Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
FL.21.1NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
FL.21.1NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
FL.21.1NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
FL.21.1NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
FL.21.1ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
FP.2.1ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-17266.7Germany
FP.2.1ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
FP.2.1NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
FP.2.1NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
FP.2.1NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
FP.2.1NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
FP.2.1NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
FP.2.1ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
XBB.1.5.92ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-17266.7Germany
XBB.1.5.92ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
XBB.1.5.92NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
XBB.1.5.92NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
XBB.1.5.92NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
XBB.1.5.92NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
XBB.1.5.92NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
XBB.1.5.92ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
XBB.1.5.42ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-17266.7Germany
XBB.1.5.42ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
XBB.1.5.42NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-5518.4China
XBB.1.5.42NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-4914.61China
XBB.1.5.42NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
XBB.1.5.42NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
XBB.1.5.42NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-893.215Hong Kong
XBB.1.5.42ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
FL.35.1ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-17266.7Germany
FL.35.1ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
FL.35.1NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
FL.35.1NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
FL.35.1NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
FL.35.1NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
FL.35.1NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
FL.35.1ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
KP.2.3.3ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
KP.3.2.5ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-20262.1Germany
KP.3.2.5ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
KP.3.2.5NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
KP.3.2.5NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-19646.7China
KP.3.2.5NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
KP.3.2.5NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
KP.3.2.5NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
KP.3.2.5ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
LU.2ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-20262.1Germany
LU.2ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
LU.2NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
LU.2NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-17999.1China
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used